Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of tumors into surrounding tissues was suppressed. These results suggest that FK228 may be useful in developing therapeutic strategies to treat synovial sarcoma.
Introduction
Synovial sarcomas are soft tissue tumors, occurring at any age but affecting mainly young adults. They are considered high-grade sarcomas because they lead to death in at least 25% of patients within the first five years following diagnosis, despite advances in treatment [1] . These sarcomas are characterized cytogenetically by the presence of a chromosomal translocation t(X;18)(p11.2;q11.2), where the SYT gene on chromosome 18
is translocated to one of the closely related SSX family genes on chromosome X [2] . The SYT protein is associated with a chromatin remodeling factor hBRM/hSNF2 alpha protein [3] , a transcriptional coactivator p300 protein [4] , and a transcriptional factor AF10 [5] . Functional studies have shown that the acidic C-terminus of SSX carries a repressor domain [3, 6, 7] . SSX proteins have been reported to show colocalization with several members of the Polycomb group proteins which are associated with transcriptional repression [7] . Splicing isoform of the SYT-SSX fusion protein was reported to accelerate the transcriptional activity and cell proliferation [8] .
Recently, we found that SYT proteins interact with mSin3A, a component of histone deacetylase (HDAC) complex, and reported that HDAC activity may be associated with T. the tumorigenesis of synovial sarcomas [9] . In the present study, by using an HDAC-specific inhibitor FK228 (depsipeptide or FR901228) which was isolated from a culture broth of Chromobacterium violaceum [10, 11] and has been reported to be effective for treating malignant T-cell lymphomas [12] , we examined the effect of HDAC inhibitor on synovial sarcoma cells with the chromosomal translocation t(X;18)(p11·2;q11·2). We found that the histone deacetylase inhibitor FK228
significantly suppressed the growth of synovial sarcoma cells as compared with that of osteosarcoma.
Materials and methods

Materials
Histone deacetylase inhibitor FK228 was provided by the Fujisawa Pharmaceutical Co.
(Osaka, Japan). FK228 was dissolved in 0.1% ethanol for in vitro experiments, and dissolved in 10% polyoxyethylene-hydrogenated castor oil (Wako Pure Chemical Industries, Osaka, Japan) and diluted with 0.9% NaCl solution for in vivo experiments.
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Cell lines
Synovial sarcoma cell lines HS-SY-2, YaFuSS and SYO-1 were provided by Dr. H.
Sonobe (National Fukuyama Hospital, Hiroshima, Japan), Dr. J. Toguchida (Institute for
Frontier Medical Sciences, Kyoto University, Japan) and Dr. A. Kawai (National Cancer
Center, Tokyo, Japan), respectively. Osteosarcoma cell line, Saos2, and human normal embryonic kidney cell line, HEK293, were purchased from American Type Culture Collection.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cells using Isogen reagent (Nippon Gene, Tokyo, Japan)
according to the manufacturer's instructions. Synthesis of cDNA was performed using ReverTra Ace (Toyobo, Tokyo, Japan). Identification of SYT-SSX cDNA was performed by PCR with SYT forward primer 5'-CAA CAG CAA GAT GCA TAC CA and SSX1 reverse primer 5'-ACA CTC CCT TCG AAT CAT TTT CG or SSX2 reverse primer 5'-GCA CTT CCT CCG AAT CAT TTC as described in a previous paper [13] . The amplified products were confirmed by DNA sequencing with an ABI3100 sequencer T. Ito et al -6 -(Applied Biosystems, Foster City, CA, USA). 
Tumor growth assay in vitro
Transfection
Human embryonic kidney 293 cells were transfected with pCMV-SYT-SSX1 and pCMV-SYT-SSX2, which contain the cDNAs amplified by RT-PCR [9] , by Effectene reagent (Qiagen, Hilden, Germany), and selected with 400 µg /ml of G418 (Sigma, St.
Louis, MO, USA) for 2 weeks. (where d1 and d2 are the two perpendicular diameters) [14] . Using another set of the inoculated 20 mice, tumors were resected at day 20 after subcutaneous inoculation of SYO-1 cells, and tumor weight was measured after the invaded internal organs were removed from them as well as possible.
The relationship between the tumor weight and FK228-treatment was statistically 
RESULTS
We confirmed the expression of fusion genes in synovial sarcoma cell lines by RT-PCR. (Table 1) , while osteosarcoma cell line, Saos2, showed 9.33 nM of IC50. Doubling time of these cells was measured, but it is not likely that the growth suppression of FK228 depends on the doubling time (Table 1) .
HS-SY-2 and YaFuSS expressed the
SYO-1 cells carrying the SYT-SSX2 gene showed more sensitive growth inhibition to FK288 at least at 24 hr than HS-SY-2 and YaFuSS both of which have the SYT-SSX1 gene.
To examine whether the SYT-SSX fusion proteins affect on the growth suppression by suggesting that it might produce some side effects.
Discussion
Recently, we reported that SYT proteins interact with mSin3A, a component of HDAC complex [9] , which suggests that HDAC activity may be associated with the tumorigenesis and malignancy of synovial sarcoma. Therefore, by using HDAC inhibitor FK228, we examined the effect of the HDAC inhibitor on growth of synovial sarcoma.
Interestingly, a significant growth inhibition was observed in the synovial sarcoma cells IC50 of osteosarcoma cell line, Saos2, was reported to be 2.6 nM at 72 hr [20] , and it was 9.33 nM at 48 hr in our results. There is a tendency that the sensitivity of Saos2 for FK228 in our experiment is lower than that of their report, but it might be caused by different subtypes of culture cells.
In the FK228-treated mice, synovial sarcoma cells were significantly reduced in size and did not show invasion into other organs, while weight reduction was transiently observed in mice treated with a high concentration of FK228. A phase1 study with FK228
showed that dose-limited toxicity caused fatigue, nausea, vomiting, and transient thrombocytopenia and neutropenia [21] . Moreover, reversible electrocardiogram (ECG) changes with ST/T wave flattening were regularly observed in 37 malignant tumor patients [21] . Although FK228 is currently expected to be used as an universal anti-neoplastic agent , it may be necessary to use the drug in low concentrations to avoid producing some of the side effects mentioned here.
SYT-SSX fusion gene has been detected in nearly 97% cases of synovial sarcomas [22] .
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At present, the 5-year overall survival rates for synovial sarcomas are 53% for the SYT-SSX1 type and 73% for the SYT-SSX2 type [23] . Our findings suggest that FK228 may be useful in developing therapeutic strategies to treat this form of sarcoma.
Identification of molecule targets of FK228 and clinical trials of FK228 are necessary to find an effective cure for malignant synovial sarcomas, and to gain insight into the mechanisms of tumorigenesis in synovial sarcomas. 
